Erratum: Adenosine A 2B receptor-mediated VEGF induction promotes diabetic glomerulopathy (Laboratory Investigation (2013) 93 (135-144) DOI: 10.1038/labinvest.2012.143);Adenosine A2B receptor-mediated VEGF induction promotes diabetic glomerulopathy

Laboratory Investigation

Volumn 93, Issue 1, 2013, Pages 135-144

  Cárdenas, Angel ^a   Toledo, Camilo ^a   Oyarzún, Carlos ^a   Sepúlveda, Angélica ^a   Quezada, Claudia ^a   Guillén Gómez, Elena ^b   Díaz Encarnación, Montserrat M ^b   Pastor Anglada, Marçal ^c   San Martín, Rody ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

adenosine receptors; diabetic nephropathy; glomerulus; VEGF

Indexed keywords

ADENINE NUCLEOTIDE; ADENOSINE; ADENOSINE A2B RECEPTOR; ALPHA SMOOTH MUSCLE ACTIN; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE 3; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; PROTEIN KINASE C ALPHA; SMALL INTERFERING RNA; STREPTOZOCIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETOGENESIS; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; GLOMERULUS; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MESANGIUM CELL; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

EID: 84871783511     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.56     Document Type: Erratum

References (47)

1. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 2006;12:62-66. (Pubitemid 43050076)
2. Gross JL, De Azevedo MJ, Silveiro SP, et al. Diabetic nephro-pathy: diagnosis, prevention, and treatment. Diab Care 2005;28:164-176. (Pubitemid 40095801)
3. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
5. Cooper M. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-219. (Pubitemid 28327814)
6. Nakagawa T. A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism. Clin Nephrol 2009;71:103-109.
7. Liu E, Morimoto M, Kitajima S, et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007;18:2094-2104. (Pubitemid 47041075)
8. Veron D, Bertuccio C, Marlier A, et al. Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 2011;54:1227-1241.
9. Cha DR, Kim NH, Yoon JW, et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 2000;77: S104-S112.
10. Gröne HJ, Simon M, Gröne EF. Expression of VEGF in renal vascular disease and renal allografts. J Pathol 1995;177:259-267.
11. Shulman K, Rosen S, Tognazzi K, et al. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996;7:661-666. (Pubitemid 27465997)
12. Kanesaki Y, Suzuki D, Uehara G, et al. VEGF gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 2005;45:288-294. (Pubitemid 40431054)
13. Baelde H, Eikmans M, Lappin D, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 2007;71:637-645. (Pubitemid 46494557)
14. Angielski S, Jakubowski Z, Pawelczyk T, et al. Renal handling and metabolism of adenosine in diabetic rats. Contrib Nephrol 1989;73:52-57.
15. Mubagwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 2001; 52:25-39. (Pubitemid 32835236)
16. Ackley MA, Governo RJ, Cass CE, et al. Control of glutamatergic neurotransmission in the rat spinal dorsal horn by the nucleoside transporter ENT1. J Physiol 2003;548:507-517. (Pubitemid 36527472)
17. Sonoki K, Iwase M, Iino K, et al. Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells. Eur J Pharmacol 2003;475:139-147. (Pubitemid 37088017)
18. Gadalla AE, Pearson T, Currie AJ, et al. AICA riboside both activates AMP-activated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus. J Neurochem 2004;88:1272-1282. (Pubitemid 38280695)
19. Choi DS, Cascini MG, Mailliard W, et al. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat Neurosci 2004;7:855-861. (Pubitemid 38989509)
20. Riksen NP, Rongen GA, Boers GH, et al. Enhanced cellular adenosine uptake limits adenosine receptor stimulation in patients with hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 2005;25:109-114. (Pubitemid 40054262)
21. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 2006;103:7895-7900.
22. Roa H, Gajardo C, Troncoso E, et al. Adenosine mediates transforming growth factor-beta 1 release in kidney glomeruli of diabetic rats. FEBS Lett 2009;583:3192-3198.
23. Fredholm B, IJzerman A, Jacobson K, et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 2011;63:1-34.
24. 2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol 2006;290:F828-F837. (Pubitemid 43724943)
25. 1 receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus. Nephron Physiol 2009;111:30-38.
26. 1 adenosine receptors augments diabetic hyperfiltration and glomerular injury. J Am Soc Nephrol 2008;19:722-730.
27. 2B receptor mediates an increase on VEGF-A production in rat kidney glomeruli. Biochem Biophys Res Commun 2008;366:180-185.
28. Quezada C, Alarcón S, Cárcamo JG, et al. Increased expression of the multidrug resistance-associated protein 1 (MRP1) in kidney glomeruli of streptozotocin induced diabetic rats. Biol Chem 2011;392:529-537.
29. Zhang Y, Geiger J, Lautt W. Improved high-pressure liquid chromato-graphic-fluorometric assay for measurement of adenosine in plasma. Am J Physiol 1999;260:G658-G664.
30. Pawelczyk T, Grden M, Rzepko R, et al. Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am J Pathol 2005;167:315-325. (Pubitemid 43026089)
31. Xia JF, Liang QL, Hu P, et al. Correlations of six related purine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients. Clin Biochem 2009;42:215-220.
32. 2B adenosine receptor-mediated induction of IL-6 promotes CKD. J Am Soc Nephrol 2011;22:890-901.
33. Ziyadeh FN. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res Clin Pract 2008;82:S38-S41.
34. Hoshi S, Nomoto K, Kuromitsu J, et al. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun 2002;290:177-184. (Pubitemid 34694480)
35. Lee EY, Chung CH, Kim JH, et al. Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes. Nephrol Dial Transplant 2006;21:1496-1503. (Pubitemid 44063123)
36. Karczewska J, Piwkowska A, Rogacka D, et al. Purinergic modulation of glucose uptake into cultured rat podocytes: effect of diabetic milieu. Biochem Biophys Res Commun 2011;404:723-727.
37. Yoo TH, Li JJ, Kim JJ, et al. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007;71:1019-1027.
38. Anderson S, Jung FF, Ingelfinger Jr. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993;265:F477-F486. (Pubitemid 23325866)
39. Zimpelmann J, Kumar D, Levine DZ, et al. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 2000;58:2320-2330.
40. Singh R, Singh AK, Alavi N, et al. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 2003;14:873-880. (Pubitemid 36359269)
41. Vidotti DB, Casarini DE, Cristovam PC, et al. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol 2004;286:F1039-F1045. (Pubitemid 38656357)
42. Lin CL, Wang FS, Hsu YC, et al. Modulation of notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy. Diabetes 2010;59:1915-1925.
43. Farías M, San Martín R, Puebla C, et al. Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol 2006;208:451-460. (Pubitemid 43993436)
44. Sakowicz M, Szutowicz A, Pawelczyk T. Insulin and glucose induced changes in expression level of nucleoside transporters and adenosine transport in rat T lymphocytes. Biochem Pharmacol 2004;68:1309-1320. (Pubitemid 39179389)
45. Aguayo C, Casado J, Gonzalez M, et al. Equilibrative nucleoside transporter 2 is expressed in human umbilical vein endothelium, but is not involved in the inhibition of adenosine transport induced by hyperglycaemia. Placenta 2005;26:641-653. (Pubitemid 41102686)
46. Guillén-Gómez E, Pinilla-Macua I, Pérez-Torras S, et al. New Role of the human equilibrative nucleoside transporter 1 (hENT1) in epithelial-to-mesenchymal transition in renal tubular cells. J Cell Physiol 2012;227:1521-1528.
47. 2B receptors on glucose homoeostasis. J Pharm Pharmacol 2006;58:1639-1645. (Pubitemid 46051680)